Page 1 |
Previous | 1 of 2 | Next |
|
small (250x250 max)
medium (500x500 max)
Large
Extra Large
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
|
Michael F. Easley
Governor
State of North Carolina
Office of the Governor
Governor's Press Office
State Capitol, Raleigh, NC 27603-8001
(919) 733-5612 - Toll Free 1-800-662-7005
FAX (919) 733-5166
For Release: IMMEDIATE Contact: Lauren Gregg
Date: Aug. 15, 2005 Phone: 919/733-5612
GOV. EASLEY ANNOUNCES $92 MILLION EXPANSION BY GLAXOSMITHKLINE JDIG and One North Carolina Fund Grants Help Company Add 200 New Jobs in Zebulon
RALEIGH – Gov. Mike Easley announced today that pharmaceutical company GlaxoSmithKline (GSK) is expanding its manufacturing facility in Zebulon, creating approximately 200 new jobs over the next four years and investing about $92 million in the area. The announcement was made possible in part by a $1.39 million Job Development Investment Grant (JDIG) and a $500,000 grant from the One North Carolina Fund.
“The competition for these types of jobs is fierce,” said Easley. “To have a world leader in pharmaceutical manufacturing expand in our state rather than across the globe is proof that our investments in education, workforce development and infrastructure are paying off.”
GSK is a global leader in the research and production of new pharmaceuticals with a wide range of prescription medicines, vaccines and consumer health care products. GSK has its headquarters in the United Kingdom. The company’s U.S. operations are based in Philadelphia and the Research Triangle Park, where about 4,800 employees work in drug research, development and commercial operations.
GlaxoSmithKline’s manufacturing facility in Zebulon first opened in 1983 and now employs about 800 people. GSK will be remodeling facilities to accommodate new production equipment at its approximately 918,000 square foot Zebulon plant in eastern Wake County. The expected average salary for the new jobs is $30,000.
“GSK is pleased to further our strong relationship with North Carolina and its citizens by expanding our operations in Zebulon,” said Christopher Viehbacher, president, U.S. Pharmaceuticals, GlaxoSmithKline. “Working together with state and local officials, we are providing new, high-quality jobs that are critical to GSK’s mission of delivering medicines to patients in the U.S. and around the world.”
Under the terms of the agreement authorized by the state Economic Investment Committee, a 12-year Job Development Investment Grant will be established. Over the life of the grant, the N.C. Department of Commerce estimates the project will:
• Generate a cumulative gross state product value of $3.98 billion
Object Description
Description
| Title | Page 1 |
| Full Text | Michael F. Easley Governor State of North Carolina Office of the Governor Governor's Press Office State Capitol, Raleigh, NC 27603-8001 (919) 733-5612 - Toll Free 1-800-662-7005 FAX (919) 733-5166 For Release: IMMEDIATE Contact: Lauren Gregg Date: Aug. 15, 2005 Phone: 919/733-5612 GOV. EASLEY ANNOUNCES $92 MILLION EXPANSION BY GLAXOSMITHKLINE JDIG and One North Carolina Fund Grants Help Company Add 200 New Jobs in Zebulon RALEIGH – Gov. Mike Easley announced today that pharmaceutical company GlaxoSmithKline (GSK) is expanding its manufacturing facility in Zebulon, creating approximately 200 new jobs over the next four years and investing about $92 million in the area. The announcement was made possible in part by a $1.39 million Job Development Investment Grant (JDIG) and a $500,000 grant from the One North Carolina Fund. “The competition for these types of jobs is fierce,” said Easley. “To have a world leader in pharmaceutical manufacturing expand in our state rather than across the globe is proof that our investments in education, workforce development and infrastructure are paying off.” GSK is a global leader in the research and production of new pharmaceuticals with a wide range of prescription medicines, vaccines and consumer health care products. GSK has its headquarters in the United Kingdom. The company’s U.S. operations are based in Philadelphia and the Research Triangle Park, where about 4,800 employees work in drug research, development and commercial operations. GlaxoSmithKline’s manufacturing facility in Zebulon first opened in 1983 and now employs about 800 people. GSK will be remodeling facilities to accommodate new production equipment at its approximately 918,000 square foot Zebulon plant in eastern Wake County. The expected average salary for the new jobs is $30,000. “GSK is pleased to further our strong relationship with North Carolina and its citizens by expanding our operations in Zebulon,” said Christopher Viehbacher, president, U.S. Pharmaceuticals, GlaxoSmithKline. “Working together with state and local officials, we are providing new, high-quality jobs that are critical to GSK’s mission of delivering medicines to patients in the U.S. and around the world.” Under the terms of the agreement authorized by the state Economic Investment Committee, a 12-year Job Development Investment Grant will be established. Over the life of the grant, the N.C. Department of Commerce estimates the project will: • Generate a cumulative gross state product value of $3.98 billion |
